These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1095 related articles for article (PubMed ID: 21294998)
1. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial. Hummel J; Westphal S; Weber-Hamann B; Gilles M; Lederbogen F; Angermeier T; Luley C; Deuschle M; Kopf D J Clin Psychiatry; 2011 Jul; 72(7):885-91. PubMed ID: 21294998 [TBL] [Abstract][Full Text] [Related]
2. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids. Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162 [TBL] [Abstract][Full Text] [Related]
3. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. McGrath PJ; Stewart JW; Fava M; Trivedi MH; Wisniewski SR; Nierenberg AA; Thase ME; Davis L; Biggs MM; Shores-Wilson K; Luther JF; Niederehe G; Warden D; Rush AJ Am J Psychiatry; 2006 Sep; 163(9):1531-41; quiz 1666. PubMed ID: 16946177 [TBL] [Abstract][Full Text] [Related]
4. Levels of lipids and apolipoproteins in three cultures. Solhpour A; Parkhideh S; Sarrafzadegan N; Asgary S; Williams K; Jungner I; Aastveit A; Walldius G; Sniderman A Atherosclerosis; 2009 Nov; 207(1):200-7. PubMed ID: 19766218 [TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein particle size, triglyceride-rich lipoproteins, and glucose tolerance in non-diabetic men with essential hypertension. Rubies-Prat J; Ordóñez-Llanos J; Martin S; Blanco-Vaca F; Molina L; Goday A; Pedro-Botet J Clin Exp Hypertens; 2001 Aug; 23(6):489-500. PubMed ID: 11478431 [TBL] [Abstract][Full Text] [Related]
6. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. Guelfi JD; Ansseau M; Timmerman L; Kørsgaard S; J Clin Psychopharmacol; 2001 Aug; 21(4):425-31. PubMed ID: 11476127 [TBL] [Abstract][Full Text] [Related]
7. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study. Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913 [TBL] [Abstract][Full Text] [Related]
8. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751 [TBL] [Abstract][Full Text] [Related]
9. Correlates of serum lipids and lipoproteins in Congolese patients with arterial hypertension. Lepira FB; M'Buyamba-Kabangu JR; Kayembe KP; Nseka MN Cardiovasc J S Afr; 2005; 16(5):249-55. PubMed ID: 16307156 [TBL] [Abstract][Full Text] [Related]
10. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J; Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589 [TBL] [Abstract][Full Text] [Related]
11. Elevated serum lipoprotein(a) in subclinical hypothyroidism. Kung AW; Pang RW; Janus ED Clin Endocrinol (Oxf); 1995 Oct; 43(4):445-9. PubMed ID: 7586619 [TBL] [Abstract][Full Text] [Related]
13. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Berneis K; Jeanneret C; Muser J; Felix B; Miserez AR Metabolism; 2005 Feb; 54(2):227-34. PubMed ID: 15690318 [TBL] [Abstract][Full Text] [Related]
15. Elevated serum lipids in veterans with combat-related chronic posttraumatic stress disorder. Solter V; Thaller V; Karlović D; Crnković D Croat Med J; 2002 Dec; 43(6):685-9. PubMed ID: 12476477 [TBL] [Abstract][Full Text] [Related]
16. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Olson EJ; Pearce GL; Jones NP; Sprecher DL Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748 [TBL] [Abstract][Full Text] [Related]
17. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN. J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296 [TBL] [Abstract][Full Text] [Related]
18. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA; J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433 [TBL] [Abstract][Full Text] [Related]
19. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Vrablik M; Fait T; Kovar J; Poledne R; Ceska R Metabolism; 2008 Aug; 57(8):1088-92. PubMed ID: 18640386 [TBL] [Abstract][Full Text] [Related]
20. [Assessment of metabolic atherosclerosis risk factors in progeny of patients with past ischemic stroke]. Mierzecki A; Bukowska H; Honczarenko K; Jastrzebska M; Millo B; Torbus-Lisiecka B Pol Arch Med Wewn; 2005 Feb; 113(2):119-29. PubMed ID: 16209232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]